Taking your Genome to the Bank
By Harry Glorikian,
Genetic Engineering & Biotechnology News
| 12. 15. 2014
What’s more valuable than your money, equally vulnerable, and unique to you? Answer: Your genome. And just like your money, your genome should be stored securely as possible and those institutions that store your genome should be regulated on how they store it, use it, and potentially share it.
As medical science advances, it’s going to be increasingly important for people to be able to control and manage access to their personal genomes. To make this possible, we need to establish a formal, well-regulated system of genome banking. Just as the government regulates the banks that hold our money, we must also have it or an equivalent group/system to govern how institutions manage our genomic data. Because it is only by guaranteeing the security and use of that information that we will be able to exploit the full potential of the growing pool of genomic data for the betterment of the individual and for mankind.
Everyone’s genomic data, after all, is potentially life saving and life changing. We’ve long known that each of us has a unique string of three...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...